JSJulie A. Semon

Julie A. Semon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julie A. Semon has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adipose Stem Cell Response to Borophosphate Bioactive Glass

    by Nada A. Abokefa, Bradley A. Bromet, Rebekah L. Blatt, Makenna S. Pickett, Richard K. Brow, Julie A. Semon

    Silicate and borate bioactive glasses have been reported to create alkaline conditions by rapidly releasing ions when reacting in aqueous solution. At certain levels, this alkaline solution can negatively affect cell viability. Adding phosphate ions to the glass composition can control the degradation rate of bioactive glasses and create a neutral pH environment. This study evaluated a series of borophosphate bioactive glasses (BPBGs) with nominal molar compositions 16Na2O-24CaO-xB2O3-(60-x)P2O5, where x = 0, 40, or 60. The phosphate (X0) glass (PBG) produced an acidic solution when dissolved in water; the borate (X60) glass (BBG) produced an alkaline solution, and the BPBG glass produced a pH-neutral solution. These three glasses were evaluated using adipose stem cells (ASCs), a cell population known for their therapeutic abilities. The effects of each glass on the pH of cell culture, ions released during degradation, and on ASC functions, including viability, migration, angiogenic ability, differentiation, and protein secretions, were evaluated. The X40 BPBG created a physiologically neutral pH in cell culture media after 24 h. The X0 phosphate glass promoted ASC migration, while the highly alkaline X60 borate increased the angiogenic ability of ASCs. These results indicate that BPBG can be used safely in cell culture studies and customized for specific biomedical applications.


  • Mesenchymal stem cells in autoimmune disease: A systematic review and meta-analysis of pre-clinical studies

    by Hailey N. Swain, Parker D. Boyce, Bradley A. Bromet, Kaiden Barozinksy, Lacy Hance, Dakota Shields, Gayla R. Olbricht, Julie A. Semon


  • Open Access

    Bioprinting with adipose stem cells and hydrogel modified with bioactive glass

    by Krishna C.R. Kolan, Apurv Saxena, Bradley A. Bromet, Lesa B. Steen, August T. Bindbeutel, Julie A. Semon, Delbert E. Day, Ming C. Leu

    AccScience Publishing is a publishing company based in Singapore. We have in our portfolio a range of high-quality, open-access, peer-reviewed journals and books from a broad spectrum of science, technology, biomedicine, engineering, education, social sciences and many more.


  • The angiogenic potential of pH‐neutral borophosphate bioactive glasses

    by Bradley A. Bromet, Nathaniel P. Blackwell, Nada Abokefa, Parker Freudenberger, Rebekah L. Blatt, Richard K. Brow, Julie A. Semon

    Borate bioactive glasses have gained attention in recent years due to their therapeutic and regenerative effects in vivo. However, borate bioactive glasses release alkaline ions, increasing the local pH and creating a toxic environment for cell culture studies. A partial compositional substitution of phosphate for borate can create a pH‐neutral glass that does not significantly affect the local pH while still releasing therapeutic ions. In the present study, a series of Na‐Ca‐borophosphate bioactive glasses with different borate‐to‐phosphate ratios was evaluated in vitro and in vivo for cytotoxicity and angiogenic effects. Compared to more basic borate glasses, the pH‐neutral glasses supported endothelial cell migration and stimulated greater blood vessel formation in a chick chorioallantoic membrane model. The results from this study indicate that these pH‐neutral glasses are promising angiogenic biomaterials for use in tissue engineering and regenerative medicine.


  • Open Access

    Mesenchymal stem cells in the treatment of osteogenesis imperfecta

    by Erica Lang, Julie A. Semon

    Osteogenesis imperfecta (OI) is a disease caused by mutations in different genes resulting in mild, severe, or lethal forms. With no cure, researchers have investigated the use of cell therapy to correct the underlying molecular defects of OI. Mesenchymal stem cells (MSCs) are of particular interest because of their differentiation capacity, immunomodulatory effects, and their ability to migrate to sites of damage. MSCs can be isolated from different sources, expanded in culture, and have been shown to be safe in numerous clinical applications. This review summarizes the preclinical and clinical studies of MSCs in the treatment of OI. Altogether, the culmination of these studies show that MSCs from different sources: 1) are safe to use in the clinic, 2) migrate to fracture sites and growth sites in bone, 3) engraft in low levels, 4) improve clinical outcome but have a transient effect, 5) have a therapeutic effect most likely due to paracrine mechanisms, and 6) have a reduced therapeutic potential when isolated from patients with OI.


  • Bioprinting with bioactive glass loaded polylactic acid composite and human adipose stem cells

    by Krishna C.R. Kolan, Julie A. Semon, August T. Bindbeutel, Delbert E. Day, Ming C. Leu


  • Bioactive borate glass triggers phenotypic changes in adipose stem cells

    by Nathan J. Thyparambil, Lisa C. Gutgesell, Bradley A. Bromet, Lauren E. Flowers, Samantha Greaney, Delbert E. Day, Julie A. Semon

    A bioactive borate glass, 13-93B3 (B3), has been used successfully in the clinic to treat chronic, nonhealing wounds without scarring. However, the mechanism by which B3 stimulates wound healing is poorly understood. Because adipose stem cells (ASCs) have been shown to have multiple roles in wound repair, we hypothesized that B3 triggers ASCs. In this study, we evaluate the effects of B3 on ASC survival, migration, differentiation, and protein secretion in vitro. In concentrations ≤10 mg/ml, B3 did not affect ASC viability under static conditions. B3 promoted the migration of ASCs but did not increase differentiation into bone or fat. B3 also decreased ASCs secretion of collagen I, PAI-1, MCP-1, DR6, DKK-1, angiogenin, IL-1, IGFBP-6, VEGF, and TIMP-2; increased expression of IL-1R and E-selectin; had a transient decrease in IL-6 secretion; and had a transient increase in bFGF secretion. Together, these results show that B3 alters the protein secretion of ASCs.


  • Adult stem cell response to doped bioactive borate glass

    by Nathan J. Thyparambil, Lisa C. Gutgesell, Cassandra C. Hurley, Lauren E. Flowers, Delbert E. Day, Julie A. Semon

    Bioactive glasses have transformed healthcare due to their versatility. Bioactive borate glass, in particular, has shown remarkable healing properties for both hard and soft tissues. Incorporating dopants into the composition of bioactive glass helps to control mechanical properties, and it increases their usefulness for clinical applications. Using a bioactive borate glass, 13-93B3 (B3), we investigated eleven dopants on the viability and migration potential of adipose stem cells (ASCs), a therapeutic source of cells used in tissue engineering and cell therapy. Our results show that under standard cell culture conditions, only Cu-doped B3 decreased cell viability, while only Y-doped B3 attracted ASCs as it dissolved in cell culture media. Using a transwell invasion assay, priming ASCs with Co, Fe, Ga, I, Sr, or Zn-doped B3 increased their homing capacity. Because there is widespread interest in optimizing and enhancing the homing efficiency of ASCs and other therapeutic cells, we then tested if priming bone marrow mesenchymal stem cells (BMSCs) with dopants also increased their homing capacity. In the case of BMSCs, there was a significant increase in invasion when cells were primed with any of the doped-B3 glasses. This work shows that incorporating dopants into borate glasses can provide a platform for a safe and efficient method that stimulates endogenous cells and healing mechanisms.